Condition: Melanoma Metastatic · Sponsor: Azienda Ospedaliera di Perugia
The association between microbiota and response to ICI-based therapy reflects the ability of bacterial metabolites to upregulate MHC class I APM component expression and/or function in cancer cells, leading to their elimination by the host's immune system. Thus, the aim of this project is to evaluate the ability of anti PD-1 combined with postbiotic, that here will be a coadjuvant of a standard immunotherapy to upregulate MHC class I APM component expression and/or function in cancer cells compared to anti PD-1 alone in first line advanced melanoma patients.
This description comes directly from the study's public registry record.
Mario Mandalà, MED · 0039 0755784211 · mario.mandala@unipg.it
Roberta Matocci, Pharmacist · 00390755784099 · roberta.matocci@ospedale.perugia.it
Always discuss trial participation with your own doctor first.
| Bari University-Oncologia medica | Bari, BA, Italy | Not Yet Recruiting |
| Torino University-Le Molinette | Torino, TO, Italy | Not Yet Recruiting |
| IRCCS Papa Giovanni II Bari | Bari, Italy | Not Yet Recruiting |
| INT Milano | Milan, Italy | Not Yet Recruiting |
| AO Perugia | Perugia, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07050940